View Older Stories

Mar 17, 2026 08:30AM Aldeyra receives FDA rejection for dry eye drug reproxalap

Mar 12, 2026 09:55AM Increasing unusual put option volume: ALDX DKS BMBL BBBY LWLG BURL DHT SCO PATH

Dec 16, 2025 03:57AM Aldeyra Therapeutics receives FDA extension for dry eye drug review

Nov 13, 2025 07:00AM Aldeyra expands RASP platform to neurological diseases

Oct 8, 2025 12:58PM Aldeyra Therapeutics (ALDX) PT Raised to $7 at Jefferies

Aug 28, 2025 07:02AM Aldeyra receives European orphan designation for eye cancer drug

Aug 19, 2025 07:01AM Aldeyra receives fast track status for retinitis pigmentosa drug

Aug 8, 2025 12:20PM Aldeyra Therapeutics (ALDX) PT Raised to $9 at Jones Trading

Jul 24, 2025 07:01AM Aldeyra gets European orphan designation for retinitis pigmentosa drug

Jul 17, 2025 07:02AM FDA accepts Aldeyra's reproxalap drug application for dry eye disease

Jun 26, 2025 08:18AM Jones Trading Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

Jun 26, 2025 07:00AM Aldeyra Therapeutics (ALDX) Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 18, 2025 03:02PM BTIG on Aldeyra Therapeutics (ALDX): 'Reproxalap Has Some Unique Attributes'

Jun 17, 2025 07:02AM Aldeyra Therapeutics (ALDX) Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 6, 2025 07:08AM ALDX SECURITIES INVESTIGATION: Aldeyra Therapeutics Investors are Notified to Contact BFA Law about Pending Securities Investigation

May 4, 2025 08:18AM ALDX INQUIRY: BFA Law Notifies Aldeyra Therapeutics, Inc. Investors to Contact the Firm About Pending Investigation into the Company

May 2, 2025 03:33PM ALDX INQUIRY ALERT: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law about Securities Investigation

May 1, 2025 03:18PM ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation

Apr 30, 2025 07:36AM ALDX NOTIFICATION: Aldeyra Therapeutics, Inc. Investors are Encouraged to Contact BFA Law about the Pending Securities Investigation

Apr 28, 2025 07:11AM ALDX SHAREHOLDER REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about Securities Investigation

Apr 26, 2025 07:08AM ALDX SHAREHOLDER ALERT: BFA Law Reminds Aldeyra Therapeutics, Inc. Investors of the Continuing Securities Investigation

Apr 24, 2025 07:36AM INVESTIGATION ALERT: Aldeyra Therapeutics, Inc. Investors are Alerted to Contact BFA Law about the Pending Securities Investigation

Apr 22, 2025 07:17AM ALDX LEGAL UPDATE: Aldeyra Therapeutics, Inc. Investors are Notified that the Company is being Investigated for Securities Violations and to Contact BFA Law

Apr 20, 2025 07:37AM ALDX INVESTORS: Investors that Suffered Losses on Aldeyra Therapeutics, Inc. are Alerted to Contact BFA Law

Apr 18, 2025 03:23PM ALDX INVESTOR NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law About How to Potentially Recover Losses

Apr 17, 2025 03:11PM ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Securities Investigation

Apr 16, 2025 08:08AM ALDEYRA THERAPEUTICS, INC. (ALDX) Investors with Losses are Notified to Contact BFA Law about Pending Securities Investigation

Apr 14, 2025 08:07AM ALDX STOCK UPDATE: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about Pending Securities Investigation

Apr 11, 2025 03:18PM ALDX STOCK ALERT: BFA Law Alerts Aldeyra Therapeutics, Inc. Investors of the Ongoing Investigation into Securities Violations

Apr 10, 2025 07:46AM ALDX CLASS REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Pending Securities Investigation

Apr 8, 2025 07:08AM ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law

Apr 7, 2025 05:17AM Aldeyra Therapeutics (ALDX) PT Lowered to $9 at BTIG

Apr 6, 2025 11:08AM ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations

Apr 4, 2025 03:33PM ALDX ALERT: BFA Law Informs Aldeyra Therapeutics, Inc. Investors to Contact the Firm about its Securities Investigation

Apr 4, 2025 02:18PM Last Night Laidlaw Published Positive Comments on Aldeyra Therapeutics (ALDX), PT $11, 'a great buying opportunity given the very limited downside and much greater upside'

Apr 4, 2025 09:34AM Aldeyra Therapeutics (ALDX) PT Lowered to $6 at Jefferies

Apr 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

Apr 3, 2025 03:18PM ALDX INVESTIGATION ALERT: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. for Securities Violations and Urges Investors to Contact the Firm

Apr 3, 2025 08:01AM Aldeyra Therapeutics (ALDX) Receives CRL from FDA for Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Apr 3, 2025 07:56AM Aldeyra Therapeutics (ALDX) Halted, News Pending

Mar 17, 2025 05:18AM BTIG Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

Feb 5, 2025 08:24AM Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders

Dec 16, 2024 06:47AM Oppenheimer on Aldeyra Therapeutics (ALDX): 'we are incrementally more optimistic about Reproxalap’s commercial potential in DED'

Nov 18, 2024 10:22AM BTIG Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

Nov 18, 2024 07:04AM Aldeyra Therapeutics (ALDX) Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Oct 3, 2024 02:14PM Laidlaw Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

Oct 3, 2024 09:30AM Oppenheimer Reiterates Outperform Rating on Aldeyra Therapeutics (ALDX)

Oct 3, 2024 07:00AM Aldeyra Therapeutics (ALDX) Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Oct 1, 2024 06:26AM William Blair Reiterates Outperform Rating on Aldeyra Therapeutics (ALDX)

Aug 8, 2024 12:42PM Aldeyra Therapeutics (ALDX) PT Raised to $10 at Jones Trading

View Older Stories